Launch week offerEnds in00h00m00s
annual Promonthly Pro
Xiaonan Zhang
Has grant
Group Leader, Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Lena Wäpplings Prize with research grand
Open Date: 2023-01-01
Close Date: 2024-01-01
Grant: Close
Swedish Childhood Cancer Fund
Open Date: 2023-01-01
Close Date: 2025-01-01
Grant: Close
Göran Gustafsson's research grant
Open Date: 2022-01-01
Close Date: 2025-01-01
Grant: Close
Jeanssons Stiftelse grant
Open Date: 2022-01-01
Close Date: 2024-01-01
Grant: Close
Swedish Childhood Cancer Fund for Research position (Forskarassistent)
Open Date: 2021-01-01
Close Date: 2025-01-01
Positions (1)
Xiaonan Zhang
Uppsala University
6 months ago
Uppsala University is advertising a PhD position in data-driven precision medicine within the Department of Immunology, Genetics and Pathology. The project sits at the intersection of bioinformatics , cancer research , molecular biology , and medical science , with a focus on understanding drug resistance and tumour relapse in aggressive solid tumours. The doctoral student will work with high-throughput sequencing data , especially single-cell RNA sequencing and bulk RNA sequencing , to identify molecular drivers of resistance and relapse and to prioritize therapeutic targets. The role includes data processing, analysis, integration, and interpretation, plus biostatistical support for other projects in the research group. The position also involves collaboration with the National Genomics Infrastructure at SciLifeLab , and the work is fully on-site in Uppsala. The position is hosted by Xiaonan Zhang , Group Leader and Associate Professor at Uppsala University. The post highlights a highly collaborative and interdisciplinary environment and is suitable for candidates with strong computational and translational research interests. Funding: The project is financially supported by Barncancerfonden and Cancerfonden . It is a four-year doctoral employment at 100% scope. No stipend amount is stated. Eligibility highlights: Applicants must already hold a Master’s degree in Molecular Medicine, Biology, Bioinformatics, or a related field, preferably with transcriptomics or cancer biology experience. Strong experience in bulk and single-cell RNA-seq analysis, tumour heterogeneity, data visualization, and English communication is required. Clinical research experience and a translational perspective are advantageous, and experience with mitochondrial function/metabolism analysis is especially valued. Application window: The last application date is 13 May 2026 . Applications are submitted through Uppsala University’s recruitment system, and the cover letter has been replaced by application questions.
6 months ago
Articles (9)
Quiescent cancer cells (QCCs) are nonproliferating cells arrested in the G0 phase, characterized by ki67low and p27high. QCCs avoid most chemotherapies, and some treatments could further lead to a higher proportion of QCCs in tumors. QCCs are also associated with cancer recurrence since they can re-enter a proliferative state when conditions are favorable. As QCCs lead to drug resistance and tumor recurrence, there is a great need to understand the characteristics of QCCs, decipher the mechanisms that regulate the proliferative–quiescent transition in cancer cells, and develop new strategies to eliminate QCCs residing in solid tumors. In this review, we discussed the mechanisms of QCC-induced drug resistance and tumor recurrence. We also discussed therapeutic strategies to overcome resistance and relapse by targeting QCCs, including (i) identifying reactive quiescent cancer cells and removing them via cell-cycle-dependent anticancer reagents; (ii) modulating the quiescence-to-proliferation switch; and (iii) eliminating QCCs by targeting their unique features. It is believed that the simultaneous co-targeting of proliferating and quiescent cancer cells may ultimately lead to the development of more effective therapeutic strategies for the treatment of solid tumors.
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2020
Year:
2020
Collaborators (6)
Fredrik Swartling
SciLifeLab Group Leader; Director of the Preclinical Cancer Treatment (PCT) Center
Uppsala University
Stig Linder
Professor
Linköpings universitet Institutionen för klinisk och experimentell medicin
Tobias Sjöblom
Professor at Uppsala University
Uppsala University
Veronica Rendo
Uppsala University
Daniel Globisch
Professor
Uppsala University
Pádraig D'Arcy
Lecturer, Researcher
Linköping University
Make your next move.
Prepare your application
Review drafts before you send them.